Differential in vitro activity of the DNA topoisomerase inhibitor idarubicin against Trypanosoma rangeli and Trypanosoma cruzi
2012
Momodou Jobe | Charles Anwuzia-Iwegbu | Ama Banful | Emma Bosier | Mubeen Iqbal | Kelly Jones | Suzanne J Lecutier | Kasimir Lepper | Matt Redmond | Andrew Ross-Parker | Emily Ward | Paul Wernham | Eleanor M Whidden | Kevin M Tyler | Dietmar Steverding
In this study the effect of eight DNA topoisomerase inhibitors on the growth Trypanosoma rangeli epimastigotes in cell culture was investigated. Among the eight compounds tested, idarubicin was the only compound that displayed promising trypanocidal activity with a half-maximal growth inhibition (GI50) value in the sub-micromolar range. Fluorescence-activated cell sorting analysis showed a reduction in DNA content in T. rangeli epimastigotes when treated with idarubicin. In contrast to T. rangeli, against Trypanosoma cruzi epimastigotes idarubicin was much less effective exhibiting a GI50 value in the mid-micromolar range. This result indicates that idarubicin displays differential toxic effects in T. rangeli and T. cruzi. Compared with African trypanosomes, it seems that American trypanosomes are generally less susceptible to DNA topoisomerase inhibitors.
显示更多 [+] 显示较少 [-]